The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 85 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 4.3 mo · strongest signal: Minimum bid deficiency (Sep 11, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity, runway < 6 months) coexists with live selling machinery (pipe). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 16, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-09-16 filing | 35 |
| Sep 16, 2026 | ▼ PIPE | “pipe” language in 8-K (8-K) filed 2026-09-16 filing | 33 |
| Sep 16, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-09-16 filing | 30 |
| Sep 16, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-09-16 (accepted 12:05 ET) filing | 23 |
| Sep 11, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-09-11 filing | 42 |
| Sep 11, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-09-11 filing | 40 |
| Sep 11, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-09-11 (accepted 08:01 ET) filing | 31 |
| Sep 9, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-09-09 filing | 42 |
| Sep 9, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-09-09 filing | 35 |
| Aug 26, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-3.1) filed 2026-08-26 filing | 40 |
| Aug 26, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-3.1) filed 2026-08-26 filing | 33 |
| Aug 26, 2026 | · Form 4 burst | 5 Form 4 filings in 30 days filing | 15 |
| Aug 24, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-24 filing | 24 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 234,696,281 (2026-05-12) -> 488,846,722 (2026-08-08), +108% filing | 40 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~4.3 months runway: liquidity $57,026,000 (cash $41,148,000 + investments $15,878,000) as of 2026-06-30, burn $158,460,694/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 36 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-94,029,000 as of 2026-06-30 filing | 31 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $57,026,000 vs current liabilities $137,783,000 filing | 22 |
SDST Stardust Power Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · screener →